Results 21 to 30 of about 89,927 (348)

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction

Frontiers in Pharmacology, 2021
Selective serotonin reuptake inhibitors (SSRIs) are a standard of care for the pharmacotherapy of patients suffering from Major Depressive Disorder (MDD). However, only one-half to two-thirds of MDD patients respond to SSRI therapy. Recently, a “multiple
Thanh Thanh L. Nguyen, Thanh Thanh L. Nguyen, Duan Liu, Ming-Fen Ho, Arjun P. Athreya, Richard Weinshilboum   +5 more
doaj   +1 more source

Right and Left-Sided Carcinoid Heart Disease in the Setting of Selective Serotonin Reuptake Inhibitor Use

JACC: Case Reports, 2020
Carcinoid heart disease is a complication of carcinoid syndrome. The role of selective serotonin reuptake inhibitors in carcinoid heart disease is unclear. We present a case of refractory heart failure due to right- and left-sided carcinoid heart disease
Jennifer Bell, MD, Maad Alhudairy, MD, Vera Kazakova, MD, Michael Johnstone, MD, Lana Tsao, MD   +4 more
doaj   +1 more source

Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder [PDF]

, 2002
Selective serotonin reuptake inhibitors have proven efficacy in the treatment of panic disorder, obsessive–compulsive disorder, post-traumatic stress disorder and social anxiety disorder.
Allgulander C, Andrew Mayers, Ansseau M, Aufdembrinke B. Abercarnil,, Ballenger JC, Barlow DH, Beekman AT, Carter RM, Chamey DS, Christel Buis, Connor KM, David Baldwin, Davidson JR, Durham RC, Durham RC, ECNP Consensus meeting, March, Fairbanks JM, Fawcett J, Feighner JP, Field MJ, Fontaine R, Gammans RE, Gelenberg AJ, Goa KL, Goldberg HL, Gould RA, Gould RA, Hedges DW, Hurst M, Keller MB, Pollack MET, Power KG, Rickels K, Rocca P, Rocca P, Sevy S, Sitsen JMA, Sramek JJ, Stahl S, Wardle J, Weizman R, Wittchen HU   +41 more
core   +1 more source

Preclinical discovery of duloxetine for the treatment of depression [PDF]

, 2012
Introduction: Affective disorders, including major depressive disorder (MDD), are among the most severely disabling mental disorders, and in many cases areIntroduction: Affective disorders, including major depressive disorder (MDD), are among the most ...
Berrocoso Domínguez, Esther María, Elorza, Julián, Micó Segura, Juan Antonio, Perez-Caballero, Laura, Torres-Sanchez, Sonia   +4 more
core   +2 more sources

Selective noradrenaline reuptake inhibitors for schizophrenia [PDF]

Cochrane Database of Systematic Reviews, 2018
Schizophrenia is frequently a chronic and disabling illness with a heterogeneous range of symptoms. The positive symptoms usually respond to antipsychotics but the cognitive and negative symptoms of schizophrenia are difficult to treat with conventional antipsychotics and significantly impact on quality of life and social outcomes.
Matthews, Paul R.L., Horder, Jamie, Pearce, Michael   +2 more
openaire   +5 more sources

Psychotropic Drugs for the Management of Chronic Pain and Itch

Pharmaceuticals, 2019
Clinical observations have shown that patients with chronic neuropathic pain or itch exhibit symptoms of increased anxiety, depression and cognitive impairment. Such patients need corrective therapy with antidepressants, antipsychotics or anticonvulsants.
Daria A. Belinskaia, Mariia A. Belinskaia, Oleg I. Barygin, Nina P. Vanchakova, Natalia N. Shestakova   +4 more
doaj   +1 more source

Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects [PDF]

, 2004
Reboxetine is a selective noradrenaline reuptake inhibitor, whereas mirtazapine acts as an antagonist at noradrenergic alpha(2), serotonin (5-HT2), 5-HT3 and histamine H-1 receptors.
Baghai, Thomas C., Laakmann, G., Schule, C.   +2 more
core   +1 more source

Fluoxetine: a case history of its discovery and preclinical development [PDF]

, 2014
Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N, Bergstrom RF, Bravo L, Bremner JD, Burrows GD, Chouinard G, Datla KP, Esther Berrocoso, Juan Antonio Mico, Kreiss DS, Laura Perez-Caballero, Lemberger L, Li Q, Lidia Bravo, Maj J, Nibuya M, Owens MJ, Rutter JJ, Sonia Torres-Sanchez, Stevens JC, Wong DT   +20 more
core   +2 more sources

The pharmacogenomics of selective serotonin reuptake inhibitors [PDF]

The Pharmacogenomics Journal, 2004
The introduction of selective serotonin (5-HT) reuptake inhibitors (SSRIs) has significantly improved the pharmacological treatment of a range of psychiatric disorders. Nevertheless, despite the undoubted advantages of antidepressant treatment in terms of improved tolerability to therapy while maintaining a high level of efficacy, not all patients ...
SERRETTI, ALESSANDRO, Artioli P.
openaire   +4 more sources

Use of selective-serotonin reuptake inhibitors and platelet aggregation inhibitors among individuals with co-occurring atherosclerotic cardiovascular disease and depression or anxiety

SAGE Open Medicine, 2016
Objective: Medications commonly used to treat heart disease, anxiety, and depression can interact resulting in an increased risk of bleeding, warranting a cautious approach in medical decision making.
J Douglas Thornton, Parul Agarwal, Usha Sambamoorthi   +2 more
doaj   +1 more source